Orbassano

• A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting
  2024-519369-24-00 5 2026-01-29 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 10 2026-01-27 Neuroendocrine tumors
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System … Recruiting
  2024-519493-39-00 5 2025-12-09 High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alt
• A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous … Recruiting
  2025-520730-28-00 4 2025-12-08 Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting
  2024-517136-21-00 5 2025-12-05 Renal Cell Carcinoma
• Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting
  2025-520555-89-00 5 2025-11-14 Metastatic castration-resistant prostate cancer (mCRPC)
• A research study to evaluate how well etavopivat works in people with sickle cell disease - Hibiscus 2 Recruiting
  2023-509175-16-00 5 2025-10-14 Sickle cell disease
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro … Recruiting
  2024-520156-22-00 4 2025-10-08 Metastatic hormone-sensitive prostate cancer
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 Lung Cancer
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting
  2024-517866-40-00 4 2025-09-29 Moderate-to-severe Asthma
• Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen Recruiting
  2024-519875-24-00 5 2025-09-26 Carcinoid syndrome
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs … Recruiting
  2024-518586-10-00 10 2025-09-18 Non-Squamous Non-Small Cell Lung Cancer
• Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting
  2024-518154-16-00 5 2025-08-27 non-small cell lung cancer
• A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting
  2024-519928-24-00 4 2025-08-21 Myelodysplastic Syndrome
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 9 2025-08-12 Metastatic castrate resistant prostate cancer - mCRPC
• CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE … Recruiting
  2024-517789-41-00 6 2025-07-04 metastatic or locally advanced renal cell carcinoma
• A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Dem … Recruiting
  2024-517450-95-00 5 2025-06-23 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt … Recruiting
  2024-515698-85-00 5 2025-06-12 Locally Advanced or Metastatic Non-small Cell Lung Cancer
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient … Recruiting
  2023-510026-32-00 5 2025-06-11 Generalized Myasthenia Gravis
• Study of Intravenous Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor to Assess Adverse Events and Change in … Recruiting
  2024-514465-18-00 9 2025-04-23 Advanced or Metastatic Non-Squamous NSCLC
• Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste … Recruiting
  2023-508507-20-00 5 2025-04-03 Locally advanced or metastatic conventional chondrosarcoma with an IDH
• A clinical trial to learn about the safety and effects of VERT-002, a new anticancer drug for the treatment of patients with advanced solid … Recruiting
  2024-512760-64-00 7 2025-02-26 locally advanced or metastatic solid tumors with MET alterations

Showing 49–72 of 208 trials